Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MDT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MDT and 80,000+ other tickers.
See exactly how MDT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MDT and 80,000+ other tickers.
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It…
First Eagle Investment Management LLC raised its holdings in shares of Medtronic PLC (NYSE: MDT) by 37.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,783,983 shares of the medical technology company's stock after purchasing an additional 3,739,288
AXQ Capital LP lifted its position in shares of Medtronic PLC (NYSE: MDT) by 109.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 28,303 shares of the medical technology company's stock after purchasing an additional 14,816 shares during the quarter. AXQ Capital LP's holdings
Medtronic executives to speak at upcoming investor conferences PR Newswire GALWAY, Ireland, Sept. 4, 2026
/PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences:
Medtronic's growth is accelerating again as its cardiovascular business expands. It's about to become a Dividend King, and its stock still looks like a bargain.